Aridis Pharmaceuticals to Present at the ROTH Capital Partners 2020 MedTech Innovation Forum on a COVID-19 Panel
The Pharma Data
OCTOBER 26, 2020
These mAbs are already of human origin and functionally optimized for high potency by the donor’s immune system; hence, they technically do not require genetic engineering or further optimization to achieve full functionality. The Company’s pipeline is highlighted below: Aridis’ Pipeline. AR-301 (VAP). AR-101 (HAP).
Let's personalize your content